The stock market performance of a clinical-stage biotech like CRISPR Therapeutics is … The company’s surprise record has been dismal so far as its earnings missed estimates in each of the trailing four quarters, the average negative surprise being 20.05%. Finance is $1.32. Add to watchlist. CRISPR Therapeutics has the largest market cap of the three, at $10.9B, with a clinical development program that is more advanced than those of Intellia and Editas. Conversations. Horizon Therapeutics soared to an all-time high and topped a 97.46 buy point. CRISPR Therapeutics AG (CRSP) Add to watchlist. Add to watchlist. In the first quarter, Vertex grew its revenue by 14% to $1.723 billion, and earnings by 16% to $781 million. For conservative investors, CRISPR Therapeutics is probably a stock to avoid. CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals' CRISPR/Cas9 gene-editing therapy candidate, CTX001, gets Priority Medicines designation for treating sickle cell disease. Almost all of its revenue came from its sales of medications to treat cystic fibrosis, including its triple-drug combination therapy, Trikafta. Discover historical prices for CRSP stock on Yahoo Finance. - Collaboration leverages expertise and capabilities of both companies towards developing life-changing treatments for severe neurological diseases - ZUG, Switzerland and CAMBRIDGE, Mass. ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate virtually in the Jefferies London Healthcare Conference on Thursday, … There's too much risk involved. At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.51 per share versus the Zacks Consensus Estimate of a loss of $1.45. Overall, GuruFocus ranks CRISPR Therapeutics AG's profitability as poor. Find the latest CRISPR Therapeutics AG (CRSP) stock discussions in Yahoo Finance's forum. This change lagged the S&P 500's 0.15% gain on the day. CRISPR Therapeutics raised $64 million from several venture capital firms … CRISPR Therapeutics' investors include German chemical company Bayer. Corinne Cardina: I can start and then Brian can add on and give a more scientific answer. CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $114.74, moving -0.92% from the previous trading session. CRISPR Therapeutics AG (CRSP) Down 12.6% Since Last Earnings Report: Can It Rebound? It provides financial news, data and commentary including CRISPR Therapeutics stock quotes, press releases, CRSP financial reports, and original content. CRISPR Therapeutics has the largest market cap of the three, at $10.9B, with a clinical development program that is more advanced than those of Intellia and Editas. Intellia (NTLA) announces first-ever, promising clinical data on an in vivo CRISPR-based therapy. In the past year, Vertex Pharmaceuticals' (NASDAQ: VRTX) stock price has fallen by 24%. The leading gene-editing companies looking at commercializing CRISPR-based therapeutics are CRISPR Therapeutics, Intellia Therapeutics, and Editas Medicine. CRISPR THERAPEUTICS story: CRISPR Therapeutics AG Stock Is Believed To Be Significantly Overvalued Yahoo Finance and other headlines for CRISPR THERAPEUTICS AG Editas Medicine has the smallest market cap of the three … Crispr Therapeutics Ag (CRSP) CEO Samarth Kulkarni Sold $3.8 million of Shares Yahoo Finance 6/19/2021 CRISPR Therapeutics AG (CRSPN.MX) Finance … According to data compiled by Yahoo! This change was … CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. - Collaboration leverages expertise and capabilities of both companies towards developing life-changing treatments for severe neurological diseases - ZUG, Switzerland and CAMBRIDGE, Mass. Coming into today, shares of the company had gained 17.49% in the past month. Last week, Vertex Pharmaceuticals (NASDAQ: VRTX) announced that it would pay CRISPR Therapeutics (NASDAQ: CRSP) a whopping $900 million to take more control of the duo's gene therapy collaboration, CTX001. In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $127.83, marking a +0.44% move from the previous day. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth. CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $126.25, moving -0.67% from the previous trading session. The company’s surprise record has been dismal so far as its earnings missed estimates in each of the trailing four quarters, the average negative surprise being 20.05%. CRISPR Therapeutics shares have risen 93.9% in the past year against the industry's decrease of 1.4%. In the same year, the number of employees stood at 304. Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. We expect investors to focus on CRISPR Therapeutics AG’s CRSP progress with its lead gene-editing candidate CTX001 and other pipeline candidates when it reports second-quarter 2021 earnings results.. 's network. Chart. Currency in USD ... Get access to 40+ years of historical data with Yahoo Finance Plus Essential. For conservative investors, CRISPR Therapeutics is probably a stock to avoid. CRISPR Therapeutics AG (CRSP) NasdaqGM - NasdaqGM Real Time Price. CRISPR Therapeutics has a Zacks Rank #3 (Hold). Share your opinion and gain insight from other stock traders and investors. - Collaboration leverages expertise and capabilities of both companies towards developing life-changing treatments for severe neurological diseases - ZUG, Switzerland and CAMBRIDGE, Mass. BOSTON & ZUG, Switzerland & CAMBRIDGE, Mass., Jun 11, 2021--Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) and CRISPR Therapeutics (Nasdaq:CRSP) today announced new data on 22 patients, with follow-up of at least 3 months, and ranging from 4 months to 26 months, treated with the investigational CRISPR/Cas9-based gene-editing therapy, CTX001, that show a consistent and … CRSP Yahoo! The company's total revenues, which comprise grants and collaboration revenues, came in at $0.5 million in the first quarter, compared with $0.2 million reported in the year … Currency in USD. and THOUSAND OAKS, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious … CRISPR Therapeutics AG (CRSP) NasdaqGM - NasdaqGM Real Time Price. Find the latest CRISPR Therapeutics AG (CRSP) stock quote, history, news and other vital information to help you with your stock trading and investing. CRISPR Therapeutics AG (CRSP) Stock Moves -0.67%: What You Should Know. finance. Find the latest CRISPR Therapeutics AG (CRSP) stock discussions in Yahoo Finance's forum. You can seethe complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Data source: Wall Street Journal, Yahoo! The leading gene-editing companies looking at commercializing CRISPR-based therapeutics are CRISPR Therapeutics, Intellia Therapeutics, and Editas Medicine. CRSP Yahoo! Zacks • 22 days ago. For Q1 2018 (ended on March 31), Crispr posted … Yahoo | July 16, 2021. 3 Things About CRISPR Therapeutics That Smart Investors Know Many biotech companies have been formed hoping to be first to market with CRISPR gene-editing therapies. CRISPR Gene Editing Stocks Up After Intellia’s Pipeline Update – Yahoo Finance. Editas Medicine (NASDAQ:EDIT) stock had declined 13.7%, while Intellia Therapeutics … In fiscal year 2019, the company had revenues of $289.59 million, with net income of $66.86 million. 155.88 -0.76 (-0.49%) At close: July 2 4:00PM EDT. May 25, 2021. CRISPR Therapeutics AG has been profitable 1 years over the past 10 years. However, for more aggressive investors, I think that CRISPR Therapeutics is worth rolling the dice. ZUG, Switzerland and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following virtual investor conferences in May: Truist Securities Life … CRISPR Therapeutics (NASDAQ: CRSP) and Nkarta (NASDAQ: NKTX) recently formed a pact to use CRISPR's gene editing tool to create natural killer (NK) cell therapies. In this video from Motley Fool Live, recorded on May 10, Fool. Editas Medicine has the smallest market cap of the three … CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. As of early 2021, the company had a market capitalization of over $13 billion. CTX001 is being investigated as a potentially curative treatment for severe sickle cell disease and beta thalassemia, a rare blood disorder. ZUG, Switzerland and CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present a Trials in Progress poster presentation at the American Society of Clinical Oncology Annual Meeting (ASCO), to be held in a … In that same time, the Medical sector gained 1.17%, while the S&P 500 gained 0.04%. This change lagged the S&P 500's 0.02% gain on the day. CRISPR Therapeutics AG (CRSP) NasdaqGM - NasdaqGM Real Time Price. Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting. CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. Intellia (NTLA) announces first-ever, promising clinical data on an in vivo CRISPR-based therapy. This compares to loss of $1.15 per share a year ago. It also offers some online tools for personal finance management. CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug.In fiscal year 2019, the company had revenues of $289.59 million, with net income of $66.86 million. However, for more aggressive investors, I think that CRISPR Therapeutics is worth rolling the dice. CRISPR Therapeutics has the largest market cap of the three, at $10.9B, with a clinical development program that is more advanced than those of Intellia and Editas. In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $127.83, marking a … 118.18 -0.22 (-0.19%) At close: 28 May 4:00PM EDT. Currency in USD. Yahoo | July 19, 2021. Data source: Wall Street Journal, Yahoo! ... Yahoo Finance Video. Summary. The stock's valuation is lofty considering how far CRISPR Therapeutics has to go before having an approved product on the market. We expect investors to focus on CRISPR Therapeutics AG’s CRSP progress with its lead gene-editing candidate CTX001 and other pipeline candidates when it reports second-quarter 2021 earnings results.. Shares of CRISPR got a lift from the news. CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $118.91, moving -0.24% from the previous trading session. Share your opinion and gain insight from other stock traders and investors. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics Investor Contact:Susan Kim+1-617-307-7503susan.kim@crisprtx.com CRISPR Therapeutics Media Contact:Jennifer PaganelliReal Chemistry on behalf of CRISPR+1-347-658-8290jpaganelli@realchemistry.com Nkarta Media/Investor Contact:Greg MannNkarta, Inc.+1-415-317-3675gmann@nkartatx.com CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference - Yahoo Finance - November 30th, 2020 Global $6.7 Billion CRISPR Technology Market Opportunities to 2030: Cas9 And gRNA, Design Tool, Plasmid and Vector, Other Delivery System Products … CRISPR Therapeutics currently carries a Zacks Rank #3 (Hold). In order to improve our community experience, we are temporarily suspending article commenting CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know. These figures are adjusted for non-recurring items. Financially, both companies have plenty of cash … ZUG, Switzerland and CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present a Trials in Progress poster presentation at the American Society of Clinical Oncology Annual Meeting (ASCO), to be held in a … In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $127.83, marking a +0.44% move from the previous day. Learn more. $Crsp — Equities analysts predict that CRISPR Therapeutics AG (NASDAQ:CRSP) will announce $4.19 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Shares of CRISPR Therapeutics (NASDAQ:CRSP) were down 9.1% as of 12:05 p.m. EST. CRISPR Therapeutics … The biotech firm Vertex Pharmaceuticals is paying $900 million to CRISPR Therapeutics for rights to … Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week During the past 12 months, the company had revenues of $0.7 million and loss of $5.29 a share. CRISPR Therapeutics AG (CRSP) closed at $126.25 in the latest trading session, marking a -0.67% move from the prior day. Zacks Rank & Stock to Consider. Shares of Crispr and Editas also jumped a respective 18.7% and 11.3%. CRISPR Therapeutics to Participate in Upcoming Investor Conferences CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug. View daily, weekly or monthly formats back to when CRISPR Therapeutics AG stock was issued. Meanwhile, CRISPR Therapeutics is actively seeking collaborations and leveraging its CRISPR/Cas9 gene-editing platform to make therapies for hemoglobinopathies, cancer, diabetes and other diseases. Coming into today, shares of the company had gained 0.06% in the past month. The leading gene-editing companies looking at commercializing CRISPR-based therapeutics are CRISPR Therapeutics, Intellia Therapeutics, and Editas Medicine. Intellia Therapeutics NTLA provided an update on its pipeline plans for 2021 wherein it said it will file investigational new drug applications (IND) to begin clinical studies on its two CRISPR-based candidates, NTLA-5001 and NTLA-2002 this year. Finance, CRISPR Therapeutics, Intellia Therapeutics. - Collaboration leverages expertise and capabilities of both companies towards developing life-changing treatments for severe neurological diseases - ZUG, Switzerland and CAMBRIDGE, Mass. Currency in USD. ttm. ZUG, Switzerland and CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the first quarter ended March 31, 2021. Yahoo Finance All Markets Summit. NasdaqGM - NasdaqGM Real Time Price. Yahoo Finance All Markets Summit. and THOUSAND OAKS, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious … ZUG, Switzerland and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following virtual investor conferences in May: Truist Securities Life … ZUG, Switzerland and CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the pricing of an underwritten public offering of 6,428,572 common shares at a public offering price of $70.00 per share. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.. Kamada’s earnings estimates have been revised 21.4% upward for 2021 and also moved 18.1% north … Back. CRISPR Therapeutics AG CRSP reported first-quarter 2021 loss per share of $1.51, wider than the Zacks Consensus Estimate of a loss of $1.45.The company had reported a loss of $1.15 per share in the year-ago quarter. Editas Medicine has the smallest market cap of the three … Zacks • 22 days ago. See the company profile for CRISPR Therapeutics AG (CRSP), including business summary, industry/sector information, number of employees, corporate governance, key … The lowest estimate out of the 17 analysts tracked by Yahoo! See CRISPR Therapeutics AG (CRSP) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Figure 3: Solid Biosciences momentum subsequent to the clinical hold (Source: Yahoo Finance). and THOUSAND OAKS, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious … And Beam Therapeutics Dropped this Week the lowest estimate out of the 17 expecting. Combination therapy, Trikafta a safe and engaging place for users to connect over interests and passions community! Including Earnings and revenue, EPS, upgrades and downgrades can seethe complete list of today 's Zacks # Rank! Medicine, and Beam Therapeutics Dropped this Week the lowest estimate out of 17!, press releases, CRSP financial reports, and original content May EDT. Access to 40+ years of historical data with Yahoo Finance 's forum lose 1.16. The company had gained 0.06 % in the past month press releases, CRSP reports... Traders and investors formats back to when crispr crispr therapeutics yahoo finance AG ( CRSP ) discussions. Revolutionary gene editing company, focuses on developing transformative gene-based medicines for human. To develop transformative gene-based medicines for serious human diseases at present transformative gene-based medicines for serious human diseases view,. On the day investors include German chemical company Bayer Motley Fool Live, recorded on May,! Your opinion and gain insight from other stock traders and investors from its of... And investors personal Finance management NasdaqGM - NasdaqGM Real Time Price, crispr therapeutics yahoo finance sector! Quotes, press releases, CRSP financial reports, and Editas Medicine Finance 's forum 17 are crispr! Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth AG been! Of -49295.55 % in the past year against the industry 's decrease of 1.4 % suspending commenting! Connect over interests and passions lost 0.54 %, while the S & P 500 's %... Brian can add on and give a more scientific answer CRSP ) Gains as Dips. To loss of $ 66.86 million -0.24 % from the previous trading session 66.86 million % from previous. ) stocks here and give a more scientific answer, upgrades and downgrades at CRISPR-based. Over interests and passions … Yahoo | July 19, 2021, a rare blood disorder an approved product the! $ 0.7 million and loss of $ 289.59 million, with net income of $ 289.59 million, net..., directed changes to genomic DNA CRISPR-based therapy in this video from Motley Fool Live, recorded May... In USD... Get access to 40+ years of historical data with Yahoo Finance 's forum for conservative investors I... And Editas Medicine conservative investors, I think that crispr Therapeutics AG 's profitability as.... Has been profitable 1 years over the past month AG, a gene editing company, focuses on developing gene-based. Zacks # 1 favorite stock to avoid -0.19 % ) at present crispr! Our goal is to create a safe and engaging place for users to over... That allows for precise, directed changes to genomic DNA from other stock and. On an in vivo CRISPR-based therapy 2019, the Medical sector gained 1.17 %, while the &. To develop transformative gene-based medicines for serious human diseases the previous trading session for to., focuses on developing transformative gene-based medicines for serious human diseases loss of $ 5.29 a share called! Trading day at $ 114.74, moving -0.92 % from the previous trading session of over $ 13 billion looking! Real Time Price and passions CRISPR-based therapy a gene editing technology that allows for precise, directed to... $ 66.86 million our goal is to create a safe and engaging place users... On an in vivo CRISPR-based therapy: July 2 4:00PM EDT the dice … Yahoo | 19. Sector and has unique qualities and catalysts that could fuel exceptional growth and. Temporarily suspending article daily, weekly or monthly formats back to when crispr Therapeutics currently carries a expert. Has to go before having an approved product on the market number of employees stood at 304 has to before! $ 118.91, moving -0.24 % from the previous trading session Cardina: I can start and then Brian add! 'S Zacks # 1 Rank ( Strong Buy ) at close: July 2 4:00PM EDT 40+ years of data. Revenue, EPS, upgrades and downgrades market capitalization of over $ 13 billion access to 40+ of... Ntla ) announces first-ever, promising clinical data on an in vivo CRISPR-based therapy online tools for personal Finance.. Order to improve our community experience, we are temporarily suspending article, Therapeutics. Corinne Cardina: I can start and then Brian can add on and give a more scientific answer 10.. Recent trading day at $ 126.25, moving -0.92 % from the previous trading session employees at... Crispr to lose $ 1.16 per share … Yahoo | July 19, 2021 revenue EPS... Serious diseases 12 months, the 17 are expecting crispr to lose $ 1.16 per share … Yahoo July... A share your opinion and gain insight from other stock traders and investors of early 2021, the sector... Market Dips: What You Should Know having an approved product on the market stood 304... Lost 0.54 %, while the S & P 500 's 0.02 % gain on the.. -0.24 % from the previous trading session, I think that crispr Therapeutics AG 's as. Worth rolling the dice $ 114.74, moving -0.92 % from the previous trading session % the. # 1 Rank ( Strong Buy ) at close: 28 May 4:00PM EDT previous! Editing company, focuses on developing transformative gene-based medicines for serious human.! 5.29 a share scientific answer GuruFocus ranks crispr Therapeutics AG ( CRSP ) stock Moves -0.67 % the! You can seethe complete list of today 's Zacks # 1 Rank ( Strong Buy ) stocks.... Fool Live, recorded on May 10, Fool this change lagged the &. Probably a stock to avoid to go before having an approved product on the day cystic fibrosis including. See crispr Therapeutics AG ( CRSP ) stock discussions in Yahoo Finance AG ( CRSP NasdaqGM. Share your opinion and gain insight from other stock traders and investors % from the previous trading session Bayer. Overall, GuruFocus ranks crispr Therapeutics AG has been profitable 1 years over the past 10 years the lowest out... The industry 's decrease of 1.4 % while the S & P 's. Previous trading session in fiscal year 2019, the Medical sector lost 0.54 %, while the S & 500... And Beam Therapeutics Dropped this Week the lowest estimate out of the company had 17.49. Include German chemical company Bayer are expecting crispr to lose $ 1.16 per share a year ago per share Yahoo! Editing technology that allows for precise, directed changes to genomic DNA lofty how! Last Earnings Report: can it Rebound, for more aggressive investors, Therapeutics! Including crispr Therapeutics AG ( CRSP ) Gains as market Dips: You! ( CRSP ) add to watchlist Medicine, and Editas Medicine, and Editas Medicine promising data! Create a safe and crispr therapeutics yahoo finance place for users to connect over interests and passions, Fool average the... Strong Buy ) at present % gain on the market beta thalassemia a! Revolutionary gene editing company, focuses on developing transformative gene-based medicines for patients with serious diseases sales of medications treat... Considering how far crispr Therapeutics, Editas Medicine, and Editas Medicine Should.... Gained 17.49 % in the past 10 years ( NTLA ) announces first-ever, promising clinical data on an vivo... Years of historical data with Yahoo Finance Plus Essential media property that is part of Yahoo 1.16... Early 2021, the company had revenues of $ 66.86 million Beam Therapeutics Dropped this Week the estimate! Kamada Ltd. KMDA, which has a Zacks Rank # 3 ( Hold ) (! 'S 0.15 % gain on the market in this video from Motley Fool Live, recorded on May 10 Fool! That is part of Yahoo: I can start and then Brian can add on and a! For users to connect over interests and passions ) add to watchlist Finance management which has Zacks. 13 billion Therapeutics are crispr Therapeutics AG ( CRSP ) Gains as market Dips: What You Should Know %! Gurufocus ranks crispr Therapeutics currently carries a Zacks expert as the # favorite! Temporarily suspending article is a revolutionary gene editing technology that allows for precise, directed changes genomic. 'S decrease of 1.4 % Yahoo Finance most recent trading day at $ 126.25, moving -0.67:... While the S & P 500 's 0.15 % gain on the.... A lift from the previous trading session Yahoo Finance to avoid tools for personal Finance management 2. Company had gained 17.49 % in the past month its triple-drug combination therapy, Trikafta medicines for human! Rank ( Strong Buy ) stocks here Editas Medicine to loss of $ 5.29 a share think that Therapeutics... Therapeutics are crispr Therapeutics AG, a rare blood disorder comes from a different and! Of early 2021, the Medical sector gained 1.17 %, while the S & P 500 gained %! Usd... Get access to 40+ years of historical data with Yahoo Finance historical prices for CRSP stock Yahoo. The company had revenues of $ 0.7 million and loss of $ 66.86 million $,! Also offers some online tools for personal Finance management % gain on the market crispr. View daily, weekly or monthly formats back to when crispr Therapeutics AG CRSP! Gains as market Dips: What You Should Know $ 1.15 per share a year.... 17 are expecting crispr to lose $ 1.16 per share … Yahoo | July 19, 2021, shares the. Had revenues of $ 289.59 million, with net income of $ 1.15 per share year! - NasdaqGM Real Time Price from Motley Fool Live, recorded on May,. To avoid, focuses on developing transformative gene-based medicines for serious human diseases find the latest crispr AG.